_________
false
קמהדע בע"מ
2
381
KAMADA LTD
Corporation no:
511524605
10991
Israel Securities Authority
Tel Aviv Stock Exchange
C003
(
Public
)
Reported via MAGNA:
30/01/2019
www.isa.gov.il
www.tase.co.il
Reference:
2019-02-008836
Time of broadcast:
13:56
13:55:27
Other Report or Announcement
Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
Please note that in the case of delayed publication of report, no changes will be allowed after the form is submitted.
Delay the publication of a report
_________
_________
1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.
2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
VP_RD_FINAL_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
TASE
Date of revision of form structure:
31/12/2018
Address:
Holtzman 2
4081
,
Rehovot
7670402
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E-mail address:
liorf@kamada.com
Company site:
www.kamada.com
Previous names of reporting entity:
Name of the Signatory:
Fhima Lior
Position of Signatory in the reporting corporation:
Director of Finance
Name of Employer Company:
Address:
Haim holtzman
2
,
Rehovot
7670402
Telephone:
08-9913168
Facsimile:
08-9912083
E-mail:
liorf@kamada.com
2